Salarius Pharmaceuticals Inc
NASDAQ:SLRX

Watchlist Manager
Salarius Pharmaceuticals Inc Logo
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Watchlist
Price: 0.535 USD -17.94% Market Closed
Market Cap: 3.1m USD

Salarius Pharmaceuticals Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Salarius Pharmaceuticals Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
Free Cash Flow
-$4.4m
CAGR 3-Years
34%
CAGR 5-Years
17%
CAGR 10-Years
13%
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$19.7B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$9.7B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
$3.3B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.9B
CAGR 3-Years
-2%
CAGR 5-Years
20%
CAGR 10-Years
20%
No Stocks Found

Salarius Pharmaceuticals Inc
Glance View

Market Cap
3.1m USD
Industry
Biotechnology

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The company is headquartered in Houston, Texas and currently employs 16 full-time employees. The company went IPO on 2015-01-29. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The firm is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.

SLRX Intrinsic Value
Not Available

See Also

What is Salarius Pharmaceuticals Inc's Free Cash Flow?
Free Cash Flow
-4.4m USD

Based on the financial report for Sep 30, 2025, Salarius Pharmaceuticals Inc's Free Cash Flow amounts to -4.4m USD.

What is Salarius Pharmaceuticals Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
13%

Over the last year, the Free Cash Flow growth was 16%. The average annual Free Cash Flow growth rates for Salarius Pharmaceuticals Inc have been 34% over the past three years , 17% over the past five years , and 13% over the past ten years .

Back to Top